UA78805C2 - Acyloxypyrrolidine derivatives, method for their preparation and therapeutic use - Google Patents

Acyloxypyrrolidine derivatives, method for their preparation and therapeutic use Download PDF

Info

Publication number
UA78805C2
UA78805C2 UAA200500286A UA2005000286A UA78805C2 UA 78805 C2 UA78805 C2 UA 78805C2 UA A200500286 A UAA200500286 A UA A200500286A UA 2005000286 A UA2005000286 A UA 2005000286A UA 78805 C2 UA78805 C2 UA 78805C2
Authority
UA
Ukraine
Prior art keywords
compound
formula
dimethoxyphenyl
sulfonyl
dihydro
Prior art date
Application number
UAA200500286A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UA78805C2 publication Critical patent/UA78805C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA200500286A 2002-07-19 2003-07-17 Acyloxypyrrolidine derivatives, method for their preparation and therapeutic use UA78805C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0209242A FR2842527B1 (fr) 2002-07-19 2002-07-19 Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique
PCT/FR2003/002262 WO2004009585A2 (fr) 2002-07-19 2003-07-17 Derives d'acyloxypyrrolidine et leur utilisation en tant que ligands des recepteurs v1b et v1a de avp

Publications (1)

Publication Number Publication Date
UA78805C2 true UA78805C2 (en) 2007-04-25

Family

ID=29797610

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200500286A UA78805C2 (en) 2002-07-19 2003-07-17 Acyloxypyrrolidine derivatives, method for their preparation and therapeutic use

Country Status (28)

Country Link
US (1) US7202267B2 (zh)
EP (1) EP1525198B1 (zh)
JP (1) JP4264414B2 (zh)
CN (1) CN100425608C (zh)
AR (1) AR040571A1 (zh)
AT (1) ATE312092T1 (zh)
AU (1) AU2003271815B8 (zh)
BR (1) BR0312800A (zh)
CA (1) CA2492224A1 (zh)
DE (1) DE60302670T2 (zh)
DK (1) DK1525198T3 (zh)
EA (1) EA008444B1 (zh)
ES (1) ES2254962T3 (zh)
FR (1) FR2842527B1 (zh)
HK (1) HK1074444A1 (zh)
HR (1) HRP20041231A2 (zh)
IL (1) IL165942A (zh)
IS (1) IS2487B (zh)
ME (1) MEP12408A (zh)
MX (1) MXPA05000822A (zh)
NO (1) NO20050292L (zh)
NZ (1) NZ537615A (zh)
PL (1) PL375309A1 (zh)
RS (1) RS20050018A (zh)
TW (1) TWI274751B (zh)
UA (1) UA78805C2 (zh)
WO (1) WO2004009585A2 (zh)
ZA (1) ZA200500478B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021534A1 (ja) 2003-08-28 2005-03-10 Taisho Pharmaceutical Co., Ltd. 1,3−ジヒドロ−2h−インドール−2−オン誘導体
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
DE102005015957A1 (de) * 2005-03-31 2006-10-05 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
CA2610400A1 (en) 2005-06-07 2006-12-14 Pharmacopeia, Inc. Azinone and diazinone v3 inhibitors for depression and stress disorders
RU2009113612A (ru) 2006-09-11 2010-10-20 Н.В. Органон (Nl) Ацетамидные производные хиназолинона и изохинолинона
CN103864658B (zh) * 2014-03-06 2016-06-15 南京工业大学 氮杂环丁酮衍生物及其制备方法与应用
CN104447489B (zh) * 2014-12-29 2017-01-11 南京工业大学 3,4-二芳基马来酰亚胺衍生物及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804114B1 (fr) * 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
ATE312092T1 (de) 2005-12-15
DE60302670T2 (de) 2006-09-07
IS2487B (is) 2008-12-15
EA200500032A1 (ru) 2005-08-25
PL375309A1 (en) 2005-11-28
FR2842527A1 (fr) 2004-01-23
HK1074444A1 (en) 2005-11-11
DE60302670D1 (de) 2006-01-12
WO2004009585A3 (fr) 2004-05-06
AU2003271815B2 (en) 2009-03-12
FR2842527B1 (fr) 2005-01-28
US20050192335A1 (en) 2005-09-01
IL165942A0 (en) 2006-01-15
JP2005537271A (ja) 2005-12-08
TWI274751B (en) 2007-03-01
WO2004009585A2 (fr) 2004-01-29
CN100425608C (zh) 2008-10-15
IL165942A (en) 2010-04-15
EA008444B1 (ru) 2007-06-29
NO20050292L (no) 2005-04-19
ES2254962T3 (es) 2006-06-16
NZ537615A (en) 2006-11-30
AU2003271815A1 (en) 2004-02-09
TW200410957A (en) 2004-07-01
ZA200500478B (en) 2006-07-26
EP1525198A2 (fr) 2005-04-27
US7202267B2 (en) 2007-04-10
HRP20041231A2 (en) 2005-02-28
DK1525198T3 (da) 2006-04-18
CA2492224A1 (en) 2004-01-29
CN1681806A (zh) 2005-10-12
RS20050018A (en) 2007-06-04
IS7641A (is) 2005-01-12
BR0312800A (pt) 2005-04-19
MXPA05000822A (es) 2005-08-29
EP1525198B1 (fr) 2005-12-07
JP4264414B2 (ja) 2009-05-20
AU2003271815B8 (en) 2009-04-30
MEP12408A (en) 2010-06-10
AR040571A1 (es) 2005-04-13

Similar Documents

Publication Publication Date Title
JP3992498B2 (ja) 新規1,3−ジヒドロ−2h−インドール−2−オン誘導体、それらの製造法およびそれらを含む医薬組成物
CN102822171B (zh) 作为自分泌运动因子抑制剂的苯并萘啶胺类
US6624164B2 (en) 1,3-dihydro-2H-indol-2-one derivatives, preparation method and pharmaceutical composition containing them
US6596732B2 (en) 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
JP5542946B2 (ja) Ccr1受容体アンタゴニストとしてのインダゾール及びピラゾロピリジン化合物
JPH09509169A (ja) エストロゲンに関連する新生物及び病気の処置に有用な新規なインドール誘導体類
WO2012035124A1 (en) Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors
JP5602639B2 (ja) 新規3−アミノアルキル−1,3−ジヒドロ−2h−インドール−2−オン誘導体、この調製、およびこの治療上の使用
TW200904436A (en) Arylamide pyrimidone derivatives
US7202267B2 (en) Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic
JP2011518213A (ja) 1,3−ジヒドロ−2H−ピロロ[3,2−b]ピリジン−2−オン誘導体、この調製、およびこの治療用途
JP2018505906A (ja) Wntシグナル伝達経路の阻害剤としての1,3,4−チアジアゾール−2−イル−ベンズアミド誘導体
RU2542980C2 (ru) Замещенные производные 3-бензофуранил-индол-2-он-3-ацетамидопиперазинов, их получение и их применение в терапии
KR20050019896A (ko) 아실옥시피롤리딘 유도체, 및 v1b 수용체 또는 v1b 및v1a 수용체 모두의 리간드로서의 그의 용도
JP2024525791A (ja) 治療に使用するためのイミダゾ[1,2-b][1,2,4]トリアゾール誘導体
TW202136243A (zh) Zeste增強子同源物2抑制劑及其用途
TW201221127A (en) Sulfamide derivatives having NPY Y5 receptor antagonistic activity